Prognostic factors in patients treated with 223Ra: The role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival

Journal of Nuclear Medicine

Volumn 56, Issue 8, 2015, Pages 1177-1184

  Etchebehere, Elba C ^a   Araujo, John C ^a   Fox, Patricia S ^a   Swanston, Nancy M ^a   Macapinlac, Homer A ^a   Rohren, Eric M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

223Ra; Fluoride PET CT; NaF PET CT; Prostate cancer; Skeletal tumor burden

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORINE 18; RADIUM CHLORIDE RA 223; FLUORODEOXYGLUCOSE F 18; RADIOISOTOPE; RADIUM; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE CANCER; BONE METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PET SCANNER; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOISOTOPE THERAPY; RADIOLOGICAL PARAMETERS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; WHOLE BODY CT; WHOLE BODY PET; BONE; BONE NEOPLASMS; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REPRODUCIBILITY; RISK; SCINTISCANNING; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; ODDS RATIO; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIUM; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84938871510     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.158626     Document Type: Article

References (41)

1. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
2. Kluetz PG, Pierce W, Maher VE, et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2014;20:9-14.
3. Joung JY, Ha YS, Kim IY. Radium Ra 223 dichloride in castration-resistant prostate cancer. Drugs Today (Barc). 2013;49:483-490.
4. Etchebehere EC, Pereira Neto CA, Lima MC, et al. Treatment of bone pain secondary to metastases using samarium-153-EDTMP. Sao Paulo Med J. 2004; 122:208-212.
5. Tolia M, Zygogianni A, Kouvaris JR, et al. The key role of bisphospho-nates in the supportive care of cancer patients. Anticancer Res. 2014;34: 23-37.
6. Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013;14:1193-1199.
7. 18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009;27:4385-4391.
8. 18F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2013;40:1809-1816.
9. Javeri H, Xiao L, Rohren E, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115: 5184-5192.
10. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;23:4652-4661.
11. 18F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40:1321-1329.
12. 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53:1829-1835.
13. 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging. 2014;41: 276-282.
14. Basu S, Saboury B, Torigian DA, Alavi A. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment. Mol Imaging Biol. 2011;13:801-811.
15. 18F-FDG PET/CT in whole-body total lesion glycolysis to predict survival in patients with pharyngeal cancer treated with definitive radiotherapy. Clin Nucl Med. 2014;39: e296-e300.
16. 18f-fluorodeox-yglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancer. Cancer Res Treat. 2014;46: 165-171.
17. 18F-FDG PET/CT in patients with pancreatic cancer. J Nucl Med. 2014;55:898-904.
18. 18F-fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:1730-1736.
19. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195-202.
20. 18F-fluoride PET/CT. J Nucl Med. 2015;56:1454.
21. 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428-432.
22. Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol. 2008;26: 1128-1134.
23. 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med. 2014;55: 1584-1590.
24. 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med. 2014;55:1260-1266.
25. 18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediasti-nal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol. 2014;32:1769-1775.
26. Ulmert D, Kaboteh R, Fox JJ, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012;62:78-84.
27. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948-957.
28. 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med. 2014;55:574-581.
29. 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28-49.
30. Schiepers C, Nuyts J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38:1970-1976.
31. 18F-fluoride PET/CT of bone, joint, and other disorders. Semin Nucl Med. 2015;45:58-65.
32. 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008; 49:68-78.
33. 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2006;36:73-92.
34. 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-297.
35. 18F PET. J Nucl Med. 1999;40:1623-1629.
36. Fizazi K, Massard C, Smith M, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2015;68:42-50
37. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664.
38. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
39. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
40. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitox-antrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154.
41. Gupta S, Potvin K, Ernst DS, Whiston F, Winquist E. ECF chemotherapy for liver metastases due to castration-resistant prostate cancer. Can Urol Assoc J. 2014;8:353-357.